stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. ICU
    stockgist
    HomeTop MoversCompaniesConcepts
    ICU logo

    SeaStar Medical Holding Corporation

    ICU
    NASDAQ
    Healthcare
    Biotechnology
    Denver, CO, US19 employeesseastarmedical.com
    $4.46
    +0.91(25.42%)

    Mkt Cap $12M

    $2.21
    $13.40

    52-Week Range

    At a Glance

    AI-generated

    SeaStar Medical Holding Corporation (ICU) reported FY 2025 net revenue of $1.23 million, a significant +814% YoY increase from $0.14 million in 2024, driven by initial commercialization of QUELIMMUNE pediatric SCD therapy following FDA HDE approval in February 2024, with first shipments in July 2024.

    $12M

    Market Cap

    $930.8K

    Revenue

    -$14M

    Net Income

    Employees19
    Fundamentals

    How The Business Makes Money

    SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.

    Industry Biotechnology
    Activity

    What Changed Recently

    Other Event
    Jan 19, 2026

    . Other Events Regaining Compliance with the $1.00 Bid Price Rule On January 20, 2026, the Company received a letter from the Nasdaq Office of General Counsel c

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    THARTharimmune, Inc.$3.29+6.82%$130M-2.0
    LPTXLeap Therapeutics, Inc.$0.77-3.15%$32M-2.6
    ATHAATHA$6.75-6.12%$27M—
    APLMApollomics, Inc.$14.95+1.53%$16M-0.6
    BLRXBioLineRx Ltd.$2.21+1.50%$10M-3.3
    CTXRCitius Pharmaceuticals, I...$0.85+1.30%$10M-0.5
    LNAILunai Bioworks Inc.$0.38-8.23%$7M-0.1
    AIMDAinos, Inc.$1.44+0.00%$6M-0.5
    Analyst View
    Company Profile
    CIK0001831868
    ISINUS81256L3024
    CUSIP81256L302
    Phone844 427 8100
    Address3513 Brighton Boulevard, Denver, CO, 80216, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice